Carfilzomib linked to higher rates of cardiovascular problems

Analysis of clinical trial data shows that patients taking cancer drug are twice as likely to experience adverse cardiac issues

via Chemical & Engineering News: Biological SCENE http://ift.tt/2lVymWU